What it's for (Indications)
- Apixaban, marketed under various brand names including Zilero, is indicated for several crucial antithrombotic applications.
- Its primary indications include the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), a condition characterized by irregular and often rapid heartbeats that can lead to blood clot formation.
- Furthermore, apixaban is approved for the prophylaxis of deep vein thrombosis (DVT), which can subsequently lead to pulmonary embolism (PE), in adult patients who have undergone elective hip or knee replacement surgery.
- It is also indicated for the treatment of existing DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy, thereby offering comprehensive management of venous thromboembolism (VTE).
- These indications underscore apixaban's role in preventing and treating life-threatening thrombotic events across diverse patient populations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of apixaban varies based on the specific indication and patient characteristics, requiring careful adherence to prescribing guidelines. For the reduction of stroke and systemic embolism in NVAF, the standard dose is 5 mg orally twice daily. A reduced dose of 2.5 mg orally twice daily is recommended for patients presenting with at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. For the prophylaxis of DVT following hip or knee replacement surgery, the recommended dose is 2.5 mg orally twice daily, initiated 12 to 24 hours post-surgery. Treatment duration is typically 35 days for hip replacement and 12 days for knee replacement. In the treatment of acute DVT and PE, the initial dose is 10 mg orally twice daily for the first 7 days, followed by 5 mg orally twice daily. For the reduction in the risk of recurrent DVT and PE, a dose of 2.5 mg orally twice daily is administered after at least 6 months of initial treatment for DVT/PE. Dose adjustments for renal impairment or concomitant medications should be made as clinically indicated. |
Safety & Warnings
Common Side Effects
- As an anticoagulant, the most significant and common adverse effect associated with apixaban is bleeding, which can range in severity from minor to life-threatening.
- Manifestations of bleeding include, but are not limited to, epistaxis (nosebleeds), hematuria (blood in urine), gastrointestinal bleeding (e.
- g.
- , melena, hematemesis), hematoma, menorrhagia (heavy menstrual bleeding), and, most critically, intracranial hemorrhage (ICH).
- Other less frequent but notable side effects include nausea, anemia (often secondary to bleeding), and hypersensitivity reactions, which can present as skin rash, pruritus, or, in severe cases, anaphylaxis.
- There have also been rare reports of elevated liver enzymes.
- Patients should be educated on the signs and symptoms of bleeding and advised to seek immediate medical attention if serious bleeding occurs.
- The risk of spinal/epidural hematoma is a serious concern, particularly in the context of neuraxial procedures.
Serious Warnings
- Black Box Warning: Apixaban carries two critical Black Box Warnings, as mandated by regulatory bodies, to highlight serious potential risks: **1. Increased Risk of Thrombotic Events on Premature Discontinuation:** Premature discontinuation of any oral anticoagulant, including apixaban, increases the risk of thrombotic events such. Patients receiving apixaban for atrial fibrillation are at an increased risk of stroke upon premature discontinuation. If apixaban must be discontinued for a reason other than pathological bleeding, such as prior to elective surgery, consideration should be given to covering the patient with another anticoagulant. Patients should be strongly advised not to discontinue therapy without consulting their prescribing physician. **2. Spinal/Epidural Hematoma:** Epidural or spinal hematomas may occur in patients treated with apixaban who are undergoing neuraxial anesthesia or spinal puncture. These hematomas may result in long-term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters, concomitant use of other drugs that affect hemostasis (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], antiplatelet agents), a history of traumatic or repeated epidural or spinal punctures, and a history of spinal deformity or spinal surgery. Physicians should consider these risks when scheduling patients for spinal procedures and monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent diagnosis and treatment, including surgical decompression, are necessary.
- Apixaban carries several critical warnings that necessitate careful patient selection and monitoring.
- There is an increased risk of thrombotic events if apixaban is prematurely discontinued without adequate alternative anticoagulation, emphasizing the importance of uninterrupted therapy or a proper transition strategy.
- The overall risk of bleeding is a paramount concern, requiring thorough assessment of individual patient risk factors, including advanced age, concomitant medications (e.
- g.
- , NSAIDs, antiplatelet agents), renal or hepatic impairment, and a history of bleeding disorders.
- Spinal or epidural hematomas are a severe potential complication in patients receiving neuraxial anesthesia or undergoing spinal puncture, which can lead to long-term or permanent paralysis.
- Factors increasing this risk include indwelling epidural catheters, concurrent use of other agents affecting hemostasis, traumatic or repeated spinal punctures, and pre-existing spinal deformities or surgery.
- Apixaban's efficacy and safety have not been established in patients with prosthetic heart valves, and it is generally not recommended for use in severe hepatic impairment due to limited clinical data.
- Furthermore, it is not recommended in patients with triple positive antiphospholipid syndrome due to an increased risk of recurrent thrombotic events.
How it Works (Mechanism of Action)
Apixaban functions as a highly selective, reversible, and direct inhibitor of Factor Xa (FXa), a pivotal enzyme within the intrinsic and extrinsic coagulation pathways. By directly targeting FXa, apixaban effectively inhibits the conversion of prothrombin to thrombin, a critical step in the coagulation cascade that ultimately leads to fibrin clot formation. This inhibitory action reduces thrombin generation and, consequently, prevents the formation and propagation of blood clots. Unlike indirect FXa inhibitors (e.g., fondaparinux) or direct thrombin inhibitors (e.g., dabigatran), apixaban does not require antithrombin III for its antithrombotic activity. It demonstrates inhibitory effects on both free and clot-bound FXa, as well as prothrombinase activity, contributing to its robust anticoagulant profile. While apixaban can prolong clotting times such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), these tests are not sensitive enough or standardized for routine monitoring of its anticoagulant effect.
Commercial Brands (Alternatives)
No other brands found for this formula.